文献速递甲状腺疾病

突变密度与异质性对甲状腺乳头状癌临床特征及缓解概率的影响

Impact of Mutation Density and Heterogeneity on Papillary Thyroid Cancer Clinical Features and Remission Probability.
PubMed 文献 · Thyroid · 2019-01-16

该研究用定制MassARRAY平台对单中心208例甲状腺乳头状癌(PTC)的19种常见遗传改变进行基因分型。结果显示71%的PTC存在致病性遗传发现,突变密度与侵袭性特征及持续性疾病风险显著相关,部分肿瘤存在遗传异质性。结论提示甲状腺癌的风险分层不能仅依赖单一遗传事件的分析。

要点

  • 71%的PTC存在致病性遗传发现,BRAFV600E和TERT启动子突变最常见。
  • 突变密度与侵袭性特征及持续性疾病风险显著相关。
  • 部分肿瘤存在遗传异质性,可能影响靶向治疗反应。

核心结论

  • 突变密度和遗传异质性对PTC临床特征及疾病结局有重要影响。
  • 甲状腺癌的准确风险分层不能仅依赖单一遗传事件的分析。
  • 部分肿瘤中存在的遗传异质性值得关注,可能影响靶向治疗反应。

研究设计与样本

  • 单中心回顾性分析208例甲状腺乳头状癌(PTC)的基因组背景。
  • 采用定制MassARRAY基因分型平台同时检测19种常见遗传改变,包括点突变和融合。

主要发现

  • 71%的PTC存在致病性遗传发现,BRAFV600E和TERT启动子突变是最常见的单等位基因改变(分别为42%和23.5%),其次为RET/PTC融合。
  • 19.2%的病例存在两个或以上点突变,并观察到融合与一个或多个点突变共存。
  • 侵袭性PTC亚组中检测到BRAFV600E与TERT启动子突变共存(12%)。
  • 多种侵袭性特征与突变密度相关,无论关联类型为仅点突变还是点突变加融合。
  • Kaplan-Meier曲线显示突变密度与持续性疾病风险较高显著相关。

临床怎么用

  • PTC的风险分层应综合评估突变密度和遗传异质性,而非仅检测单一遗传事件。
  • 对存在多重遗传改变或异质性的肿瘤,需关注其与侵袭性特征及持续性疾病风险的关联。

局限性

  • 研究为单中心系列,结论外推需谨慎。
  • 原文未报告样本量、P值等具体统计细节。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The need to integrate the classification of cancer with information on the genetic pattern has emerged in recent years for several tumors. METHODS: The genomic background of a large series of 208 papillary thyroid cancers (PTC) followed at a single center was analyzed by a custom MassARRAY genotyping platform, which allows the simultaneous detection of 19 common genetic alterations, including point mutations and fusions. RESULTS: Of the PTCs investigated, 71% were found to have pathognomonic genetic findings, with BRAFV600E and TERT promoter mutations being the most frequent monoallelic alterations (42% and 23.5%, respectively), followed by RET/PTC fusions. In 19.2% of cases, two or more point mutations were found, and the co-occurrence of a fusion with one or more point mutation(s) was also observed. Coexisting BRAFV600E and TERT promoter mutations were detected in a subgroup of aggressive PTCs (12%). A correlation between several aggressive features and mutation density was found, regardless of the type of association (i.e., only point mutations, or point mutations and fusions). Importantly, Kaplan-Meier curves demonstrated that mutation density significantly correlated with a higher risk of persistent disease. In most cases, the evaluation of the allelic frequencies normalized for the cancer cell content indicated the presence of the monoallelic mutation in virtually all tumor cells. A minority of cases was found to harbor low allelic frequencies, consistent with the presence of the mutations in a small subset of cancer cells, thus indicating tumor heterogeneity. Consistently, the presence of coexisting genetic alterations with different allelic frequencies in some tumors suggests that PTC can be formed by clones/subclones with different mutational profiles. CONCLUSIONS: A large mono-institutional series of PTCs was fully genotyped by means of a cost- and time-effective customized panel, revealing a strong impact of mutation density and genetic heterogeneity on the clinical features and on disease outcomes, indicating that an accurate risk stratification of thyroid cancer cannot rely on the analysis of a single genetic event. Finally, the heterogeneity found in some tumors warrants attention, since the occurrence of this phenomenon is likely to affect response to targeted therapies.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Colombo C, Muzza M, Proverbio MC, et al. Impact of Mutation Density and Heterogeneity on Papillary Thyroid Cancer Clinical Features and Remission Probability. Thyroid. 2019. PMID: 30501571. doi:10.1089/thy.2018.0339

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。